How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 446-450

  Mantzaris, Gerassimos J ^a   Roussos, Anastasios ^a,c   Kalantzis, Chryssostomos ^b   Koilakou, Stavroula ^a   Raptis, Nickolaos ^a   Kalantzis, Nickolaos ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NIMTS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Adherence; Azathioprine; Crohn's disease; Remission

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANTIMETABOLITES; AZATHIOPRINE; CROHN DISEASE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; RISK FACTORS;

EID: 34247597731     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20041     Document Type: Article

References (29)

1. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978;2(8097):955-957.
2. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
3. Candy S, Wright J, Gerber M, et al. Controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
4. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
5. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
6. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
7. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
8. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol. 2000;24:66-73.
9. Lemann M, Mary JY, Colombel JF, et al; Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812-1818.
10. Murphy DA, Sarr M, Durako SJ, et al; Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249-255.
11. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794-811.
12. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800-2805.
13. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
14. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
15. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
16. Pallis AG, Vlachonikolis IG, Mouzas IA. Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire. Digestion. 2001;63:240-246.
17. Haynes RB. Determinants of compliance. In: Haynes RB, Taylor DW, eds. Compliance in health care. Baltimore, MD: Johns Hopkins University Press; 1979:130-168.
18. Agras WS. Understanding compliance with the medical regimen: the scope of the problem and a theoretical perspective. Arthritis Care Res. 1989;2:S2-S7.
19. Spiro H. Compliance, adherence and hope. J Clin Gastroenterol 2001;32:5.
20. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2:757-764.
21. Liu H, Kaplan AH, Wenger NS. Measuring patient adherence. Ann Intern Med. 2002;137:72-73.
22. DiMatteo MR, Hays RD, Sherbourne CD. Adherence to cancer regimens: implications for treating the older patient. Oncology. 1992;6:50-57.
23. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of non-compliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol. 2001;32:66-68.
24. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242.
25. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421-427.
26. Lopez San Roman A, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97:249-257.
27. Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:1006-1012.
28. Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther. 2003;17:69-73.
29. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305(6844):20-22.